# Efficacy and Tolerability of Tasipimidine in Sleepless Patients

> **NCT06956495** · PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 190 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** Tasipimidine
- **DRUG:** Tasipimidine placebo

## Key facts

- **NCT ID:** NCT06956495
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-20
- **Primary completion:** 2025-09-11
- **Final completion:** 2025-09-24
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06956495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06956495, "Efficacy and Tolerability of Tasipimidine in Sleepless Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06956495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*